Scarica l'app Stockscreener
6.91
1.14%
-0.08
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALGS Giù?
Forum
Previsione
Precedente Chiudi:
$6.99
Aprire:
$7.01
Volume 24 ore:
49,881
Relative Volume:
0.69
Capitalizzazione di mercato:
$42.52M
Reddito:
$7.97M
Utile/perdita netta:
$-75.74M
Rapporto P/E:
-0.2845
EPS:
-24.2853
Flusso di cassa netto:
$-85.33M
1 W Prestazione:
-5.60%
1M Prestazione:
-25.22%
6M Prestazione:
-9.67%
1 anno Prestazione:
-67.11%
Intervallo 1D:
$6.905
$7.71
Intervallo di 1 settimana:
$6.905
$7.76
Portata 52W:
$3.76
$24.32
Aligos Therapeutics Inc Stock (ALGS) Company Profile
Nome
Aligos Therapeutics Inc
Settore
Industria
Telefono
(800) 466-6059
Indirizzo
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO
Compare ALGS vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALGS
Aligos Therapeutics Inc
|
6.91 | 43.01M | 7.97M | -75.74M | -85.33M | -24.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Aligos Therapeutics Inc Stock (ALGS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-18 | Ripresa | H.C. Wainwright | Buy |
| 2024-08-19 | Iniziato | H.C. Wainwright | Buy |
| 2023-01-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-01-06 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-03-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-01-07 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-01-06 | Downgrade | Jefferies | Buy → Hold |
| 2021-09-09 | Iniziato | SVB Leerink | Outperform |
| 2021-05-17 | Ripresa | Piper Sandler | Overweight |
| 2020-11-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-11-10 | Iniziato | JP Morgan | Overweight |
| 2020-11-10 | Iniziato | Jefferies | Buy |
| 2020-11-10 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Aligos Therapeutics Inc Borsa (ALGS) Ultime notizie
Rally Mode: What analysts say about Aligos Therapeutics Inc stockMarket Performance Summary & Free Long-Term Investment Growth Plans - baoquankhu1.vn
Aligos Therapeutics: Pipeline Progress and Financial Runway Under the Microscope - AD HOC NEWS
(ALGS) Volatility Zones as Tactical Triggers - Stock Traders Daily
Aligos Therapeutics Appoints New Principal Accounting Officer - TipRanks
Aligos Therapeutics Grants Non-Qualified Stock Options to New Employees as Part of Inducement Plan - Quiver Quantitative
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Biotech Aligos gives new hires options on 81,100 shares - Stock Titan
Aligos Therapeutics secures $105 million in private placement - MSN
Price-Driven Insight from (ALGS) for Rule-Based Strategy - Stock Traders Daily
Aligos Therapeutics edges higher after update on Phase 2 HBV trial - MSN
Aligos Therapeutics stock maintains Buy rating at H.C. Wainwright on pevifoscorvir progress - Investing.com
Aligos reports progress on Phase 2 hepatitis B drug study By Investing.com - Investing.com Australia
Aligos Therapeutics stock rises on Phase 2 HBV study progress By Investing.com - Investing.com Nigeria
Aligos Therapeutics stock rises on Phase 2 HBV study progress - Investing.com
Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates - Investing News Network
ALGS Executive Vice President and Chief Medical Officer Resigns - GuruFocus
Aligos Therapeutics (ALGS) Updates on Phase 2 Study for Hepatitis B Treatment - GuruFocus
Aligos reports progress on Phase 2 hepatitis B drug study - Investing.com
Aligos Therapeutics provides phase 2 B-SUPREME study progress updates - marketscreener.com
Aligos Therapeutics, Inc. Provides Phase 2 B-Superme Study Progress Updates - marketscreener.com
ALGS: Piper Sandler to Host Virtual Meeting on January 22 - GuruFocus
Lobbying Update: $80,000 of ALIGOS THERAPEUTICS INC. lobbying was just disclosed - Quiver Quantitative
(ALGS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Aligos’ New Phase 1 Hepatitis B Study Signals Steady Progress in High-Need Market - TipRanks
Aligos therapeutics appoints James Hassard as chief commercial officer By Investing.com - Investing.com Nigeria
Geopolitics Watch: Why retail investors favor Aligos Therapeutics Inc stockPrice Action & Risk Controlled Daily Plans - Bộ Nội Vụ
Why retail investors favor Aligos Therapeutics Inc. stockInflation Watch & Verified Swing Trading Watchlist - Bộ Nội Vụ
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer - Investing News Network
Aligos Therapeutics looks to raise $105 million in private placement - MSN
Aligos therapeutics appoints James Hassard as chief commercial officer - Investing.com India
Aligos Therapeutics strengthens senior leadership team with the appointment of James Hassard as executive vice president, chief commercial officer - marketscreener.com
Aligos Therapeutics Presents Positive Data at HEP-DART 2025 - Investing News Network
Why Aligos Therapeutics Inc. stock could be next big winnerJuly 2025 Recap & Accurate Entry and Exit Point Alerts - ulpravda.ru
Aligos Therapeutics (NASDAQ:ALGS) Earns Buy Rating from Analysts at UBS Group - Defense World
UBS Group Upgrades Aligos Therapeutics (NASDAQ:ALGS) to "Strong-Buy" - MarketBeat
Why analysts upgrade Aligos Therapeutics Inc. stock2025 Market Trends & Community Consensus Trade Signals - Улправда
How resilient is Aligos Therapeutics Inc. stock in market downturnsJuly 2025 Rallies & Free Fast Entry Momentum Trade Alerts - Улправда
Why analysts remain bullish on Aligos Therapeutics Inc. stockJuly 2025 Movers & Daily Volume Surge Trade Alerts - Улправда
Trend Recap: Does Aligos Therapeutics Inc. stock trade at a discount to peers2025 Price Action Summary & Daily Stock Trend Watchlist - ulpravda.ru
Onco3R Therapeutics Appoints Lawrence Blatt as Chair of the Board for Onco3R Therapeutics - manilatimes.net
UBS Initiates Coverage of Aligos Therapeutics (ALGS) with Buy Recommendation - Nasdaq
UBS Initiates Coverage on ALGS with a Buy Rating and $20 PT | AL - GuruFocus
Here's Why Aligos Therapeutics (NASDAQ:ALGS) Must Use Its Cash Wisely - Yahoo Finance
Aligos Therapeutics stock initiated with Buy rating at UBS on liver disease pipeline - Investing.com
(ALGS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Is Aligos Therapeutics Inc a good long term investmentValue Traps to Avoid & Diversify Intelligently to Avoid Big Hits - earlytimes.in
Head to Head Review: Xilio Therapeutics (NASDAQ:XLO) and Aligos Therapeutics (NASDAQ:ALGS) - Defense World
Aligos Therapeutics Inc 5WK0 Stock Analysis and ForecastEquity Performance Review & Small Investment Portfolio Tips - earlytimes.in
Aligos Therapeutics Inc Azioni (ALGS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):